Skip to main content
Christopher Lieu, MD, Oncology, Aurora, CO, University of Colorado Hospital

ChristopherHanyoungLieuMD

Oncology Aurora, CO

Associate Professor, University of Colorado School of Medicine

Dr. Lieu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lieu's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 2004 - 2007
  • Wake Forest School of Medicine of Wake Forest Baptist Medical Center
    Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2004

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2008 - 2026
  • CO State Medical License
    CO State Medical License 2007 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Cancer Immunotherapy with Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis  
    Sharon Solomon, Christopher H Lieu, Ashvini Reddy, Leisha A Emens, S Lindsey Davis, Lingmin He, JAMA

Lectures

  • Addressing Survivorship in Cancer Care 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

  • Colorectal Cancer in Young People
    Colorectal Cancer in Young PeopleMarch 21st, 2023
  • FDA Committee Unanimously Rejects 131-I-Omburtamab for Neuroblastoma
    FDA Committee Unanimously Rejects 131-I-Omburtamab for NeuroblastomaOctober 28th, 2022
  • PI3K Inhibitor Fails Standard with FDA Advisory Committee
    PI3K Inhibitor Fails Standard with FDA Advisory CommitteeSeptember 23rd, 2022
  • Join now to see all

Hospital Affiliations